PDCD1 and hypothyroidism: Conversely, sequential therapy of anti-PD-1 and anti-PD-L1 was associated with a decreased risk of hypothyroidism (compared with anti-PD-1 monotherapy, OR, 0.44; 95% CI, 0.25-0.75; P < .01).